Published in Sci Transl Med on October 06, 2010
Safety and Efficacy of AIN457 in Noninfectious Uveitis | NCT00685399
Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science (2011) 6.19
Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov (2012) 4.70
The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α. Nat Med (2012) 2.66
In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease. Nat Med (2014) 2.54
Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol (2011) 2.53
Rorγt+ innate lymphocytes and γδ T cells initiate psoriasiform plaque formation in mice. J Clin Invest (2012) 2.40
Th17 cells in immunity to Candida albicans. Cell Host Microbe (2012) 1.97
IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol (2011) 1.95
The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol (2015) 1.89
Recent advances in the IL-17 cytokine family. Curr Opin Immunol (2011) 1.86
The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. Annu Rev Pathol (2012) 1.80
Deciphering the role of Th17 cells in human disease. Trends Immunol (2011) 1.76
Proatherogenic conditions promote autoimmune T helper 17 cell responses in vivo. Immunity (2014) 1.75
The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol (2012) 1.71
Meta-analysis derived (MAD) transcriptome of psoriasis defines the "core" pathogenesis of disease. PLoS One (2012) 1.70
IL-17 family: cytokines, receptors and signaling. Cytokine (2013) 1.66
Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther (2011) 1.61
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol (2013) 1.59
Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog (2013) 1.54
The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases. Immunology (2011) 1.53
T helper 17 cell heterogeneity and pathogenicity in autoimmune disease. Trends Immunol (2011) 1.47
IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol (2012) 1.46
IL-17 and TNF-α sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. J Immunol (2012) 1.44
Ursolic acid suppresses interleukin-17 (IL-17) production by selectively antagonizing the function of RORgamma t protein. J Biol Chem (2011) 1.43
IL-17 cytokines in immunity and inflammation. Emerg Microbes Infect (2013) 1.37
Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy. Arthritis Res Ther (2011) 1.33
Dissecting the psoriasis transcriptome: inflammatory- and cytokine-driven gene expression in lesions from 163 patients. BMC Genomics (2013) 1.32
IL-17 response mediates acute lung injury induced by the 2009 pandemic influenza A (H1N1) virus. Cell Res (2011) 1.30
Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology (2014) 1.25
Pathology of asthma. Front Microbiol (2013) 1.25
The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol (2013) 1.24
IL-17 in obesity and adipogenesis. Cytokine Growth Factor Rev (2010) 1.23
Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J Exp Med (2013) 1.21
New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol (2012) 1.21
Trial Watch: Immunostimulatory cytokines. Oncoimmunology (2012) 1.19
Mechanisms underlying helper T-cell plasticity: implications for immune-mediated disease. J Allergy Clin Immunol (2013) 1.19
TH17 Cells in Autoimmunity and Immunodeficiency: Protective or Pathogenic? Front Immunol (2012) 1.17
Developments in therapies for spondyloarthritis. Nat Rev Rheumatol (2012) 1.17
T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity. J Clin Invest (2015) 1.17
The deubiquitinase A20 mediates feedback inhibition of interleukin-17 receptor signaling. Sci Signal (2013) 1.16
Neither IL-17A mRNA nor IL-17A protein are detectable in Langerhans cell histiocytosis lesions. Mol Ther (2011) 1.12
A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis. J Interferon Cytokine Res (2011) 1.12
Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis. Proc Natl Acad Sci U S A (2015) 1.09
FcγRIIIa-Syk Co-signal Modulates CD4+ T-cell Response and Up-regulates Toll-like Receptor (TLR) Expression. J Biol Chem (2015) 1.09
Putting together the psoriasis puzzle: an update on developing targeted therapies. Dis Model Mech (2012) 1.09
Highlights of 10 years of immunology in Nature Reviews Immunology. Nat Rev Immunol (2011) 1.06
IL-17 signaling in host defense against Candida albicans. Immunol Res (2011) 1.06
Genetic controls of Th17 cell differentiation and plasticity. Exp Mol Med (2011) 1.05
Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection. J Clin Invest (2011) 1.05
Jakpot! New small molecules in autoimmune and inflammatory diseases. Exp Dermatol (2014) 1.05
Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential. Ther Adv Musculoskelet Dis (2013) 1.05
Hiding under the skin: Interleukin-17-producing γδ T cells go under the skin? Nat Med (2012) 1.03
IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model. PLoS One (2014) 1.01
Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J Immunol (2014) 1.00
Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. Rheumatology (Oxford) (2014) 0.98
Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy? Arthritis Res Ther (2014) 0.97
Autoreactive T Cells in Human Smokers is Predictive of Clinical Outcome. Front Immunol (2012) 0.96
The IL-17A-producing CD8+ T-cell population in psoriatic lesional skin comprises mucosa-associated invariant T cells and conventional T cells. J Invest Dermatol (2014) 0.96
Homeostatic regulation of Salmonella-induced mucosal inflammation and injury by IL-23. PLoS One (2012) 0.95
IL-17-mediated Bcl-2 expression regulates survival of fibroblast-like synoviocytes in rheumatoid arthritis through STAT3 activation. Arthritis Res Ther (2013) 0.95
The IL23R A/Gln381 allele promotes IL-23 unresponsiveness in human memory T-helper 17 cells and impairs Th17 responses in psoriasis patients. J Invest Dermatol (2013) 0.95
Targeting of interleukin-17 in the treatment of psoriasis. Clin Cosmet Investig Dermatol (2014) 0.93
Neutralization of IL-17 ameliorates uveitis but damages photoreceptors in a murine model of spondyloarthritis. Arthritis Res Ther (2012) 0.93
Transcriptional and epigenetic networks of helper T and innate lymphoid cells. Immunol Rev (2014) 0.93
The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses. Clin Exp Immunol (2013) 0.93
A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther (2013) 0.92
Comparative transcriptomic analyses of atopic dermatitis and psoriasis reveal shared neutrophilic inflammation. J Allergy Clin Immunol (2012) 0.92
IL-17A increases ADP-induced platelet aggregation. Biochem Biophys Res Commun (2011) 0.92
Microbiota: host interactions in mucosal homeostasis and systemic autoimmunity. Cold Spring Harb Symp Quant Biol (2014) 0.92
The role of IL-17-secreting mast cells in inflammatory joint disease. Nat Rev Rheumatol (2012) 0.92
Nociceptive neurons detect cytokines in arthritis. Arthritis Res Ther (2014) 0.92
Signaling through IL-17C/IL-17RE is dispensable for immunity to systemic, oral and cutaneous candidiasis. PLoS One (2015) 0.92
Promising new treatments for psoriasis. ScientificWorldJournal (2013) 0.91
Diversity of IL-17-producing T lymphocytes. Cell Mol Life Sci (2012) 0.91
In vivo induction of cutaneous inflammation results in the accumulation of extracellular trap-forming neutrophils expressing RORγt and IL-17. J Invest Dermatol (2013) 0.91
Inflammation and bone destruction in arthritis: synergistic activity of immune and mesenchymal cells in joints. Front Immunol (2012) 0.91
Enhanced Th17-cell responses render CCR2-deficient mice more susceptible for autoimmune arthritis. PLoS One (2011) 0.91
Topical delivery of anti-TNFα siRNA and capsaicin via novel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo. J Control Release (2013) 0.91
Elevated serum levels of interleukin-17A in children with autism. J Neuroinflammation (2012) 0.91
Mice genetically inactivated in interleukin-17A receptor are defective in long-term control of Mycobacterium tuberculosis infection. Immunology (2013) 0.91
Crystal structures of interleukin 17A and its complex with IL-17 receptor A. Nat Commun (2013) 0.89
Enhanced and persistent levels of interleukin (IL)-17⁺ CD4⁺ T cells and serum IL-17 in patients with early inflammatory arthritis. Clin Exp Immunol (2013) 0.88
Rheumatoid arthritis and the era of biologic therapy. Inflammopharmacology (2012) 0.88
Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapy. Dermatol Ther (Heidelb) (2014) 0.88
Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature (2015) 0.88
CIKS/Act1-mediated signaling by IL-17 cytokines in context: implications for how a CIKS gene variant may predispose to psoriasis. J Immunol (2012) 0.87
IL-23 dependent and independent stages of experimental arthritis: no clinical effect of therapeutic IL-23p19 inhibition in collagen-induced arthritis. PLoS One (2013) 0.87
Nuclear receptor NR4A2 orchestrates Th17 cell-mediated autoimmune inflammation via IL-21 signalling. PLoS One (2013) 0.87
Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implications. AAPS J (2014) 0.87
Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study. Clin Vaccine Immunol (2012) 0.87
Clinical consequences of targeting IL-17 and TH17 in autoimmune and allergic disorders. Curr Allergy Asthma Rep (2013) 0.87
Endogenous interleukin-10 constrains Th17 cells in patients with inflammatory bowel disease. J Transl Med (2011) 0.86
The anaphase-promoting complex protein 5 (AnapC5) associates with A20 and inhibits IL-17-mediated signal transduction. PLoS One (2013) 0.86
Orphan receptor IL-17RD tunes IL-17A signalling and is required for neutrophilia. Nat Commun (2012) 0.86
Janus-like effects of type I interferon in autoimmune diseases. Immunol Rev (2012) 0.86
Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a. J Exp Med (2016) 0.86
Intestinal neuroendocrine cells and goblet cells are mediators of IL-17A-amplified epithelial IL-17C production in human inflammatory bowel disease. Mucosal Immunol (2014) 0.85
IL-17A mediates early post-transplant lesions after heterotopic trachea allotransplantation in Mice. PLoS One (2013) 0.84
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum (2010) 18.82
2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis (2010) 12.12
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet (2010) 9.90
Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell (2005) 9.01
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology (2012) 8.29
Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet (2008) 7.07
Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology (2006) 5.79
Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA (2003) 5.33
Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther (2007) 5.02
Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum (2005) 4.64
Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol (2006) 3.86
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet (2013) 3.83
MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha. Science (2002) 3.78
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum (2005) 3.64
Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol (2011) 3.63
Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet (2009) 3.52
Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.26
Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology (2013) 2.99
International clinical recommendations on scar management. Plast Reconstr Surg (2002) 2.88
Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther (2008) 2.59
Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther (2006) 2.59
Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med (2006) 2.53
An SNP in the 5'-UTR of GDF5 is associated with osteoarthritis susceptibility in Europeans and with in vivo differences in allelic expression in articular cartilage. Hum Mol Genet (2007) 2.52
Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol (2004) 2.45
In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology (2013) 2.43
Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum (2011) 2.41
Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology (2006) 2.35
Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum (2007) 2.35
Evaluation of sub-Tenon triamcinolone acetonide injections in the treatment of scleritis. Am J Ophthalmol (2009) 2.35
Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum (2012) 2.31
Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest (2003) 2.27
Defective lymphocyte chemotaxis in beta-arrestin2- and GRK6-deficient mice. Proc Natl Acad Sci U S A (2002) 2.26
Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ (2009) 2.23
Association of anti-citrullinated vimentin and anti-citrullinated α-enolase antibodies with subsets of rheumatoid arthritis. Arthritis Rheum (2012) 2.22
One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology (2012) 2.20
Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum (2008) 2.17
Plasmapheresis for lupus retinal vasculitis. Arch Ophthalmol (2006) 2.13
The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum (2004) 2.12
Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest (2009) 2.12
Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum (2011) 2.11
Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood (2002) 2.11
The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol (2002) 2.10
Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum (2010) 2.08
Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology (Oxford) (2010) 2.06
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis (2012) 2.06
Uveitis in patients with autoimmune hepatitis. Am J Ophthalmol (2009) 2.02
Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum (2008) 2.02
Immunoglobulin G4+ clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis. Hepatology (2013) 2.02
Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol (2005) 2.01
Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol (2011) 1.98
DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther (2005) 1.96
Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology (2012) 1.95
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum (2010) 1.94
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2011) 1.93
Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging. Arthritis Rheum (2002) 1.92
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis (2014) 1.88
Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol (2008) 1.87
Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice. Arthritis Rheum (2009) 1.87
Retinal thickness analysis by race, gender, and age using Stratus OCT. Am J Ophthalmol (2009) 1.86
Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype. Arthritis Rheum (2008) 1.86
Clinical characteristics of a large cohort of patients with scleritis and episcleritis. Ophthalmology (2011) 1.85
Beta-arrestin-2 regulates the development of allergic asthma. J Clin Invest (2003) 1.85
Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis. Arthritis Rheum (2008) 1.84
Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood (2006) 1.83
Transcriptional patterns in both host and bacterium underlie a daily rhythm of anatomical and metabolic change in a beneficial symbiosis. Proc Natl Acad Sci U S A (2010) 1.82
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis (2012) 1.78
Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis (2012) 1.77
Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum (2009) 1.77
Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum (2010) 1.77
Cyclosporine for ocular inflammatory diseases. Ophthalmology (2010) 1.75
The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study. Arthritis Rheum (2009) 1.75
Peripheral joint inflammation in early onset spondyloarthritis is not specifically related to enthesitis. Ann Rheum Dis (2013) 1.74
Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum (2004) 1.73
Cerebral palsy is characterized by protein mediators in cord serum. Ann Neurol (2004) 1.73
Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control. J Infect Dis (2003) 1.71
Analysis of pediatric uveitis cases at a tertiary referral center. Ophthalmology (2005) 1.69
Relapsing polychondritis: a clinical review. Semin Arthritis Rheum (2002) 1.68
Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders. Arthritis Rheum (2008) 1.67
Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: Implications for pathogenesis and evaluation of treatment. Arthritis Rheum (2002) 1.67
Interleukin-12 induces salivary gland dysfunction in transgenic mice, providing a new model of Sjögren's syndrome. Arthritis Rheum (2009) 1.67
Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology (2007) 1.66
Rapid effect of inhaled fluticasone propionate on airway responsiveness to adenosine 5'-monophosphate in mild asthma. J Allergy Clin Immunol (2002) 1.63
The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. Arthritis Rheum (2008) 1.63
Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology (2011) 1.62
Reliability of computerized image analysis for the evaluation of serial synovial biopsies in randomized controlled trials in rheumatoid arthritis. Arthritis Res Ther (2005) 1.62
Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. Arthritis Rheum (2006) 1.62
Nonsteroidal anti-inflammatory therapy and recurrent acute anterior uveitis. Ocul Immunol Inflamm (2010) 1.62
Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum (2006) 1.62
Adverse effects of smoking on patients with ocular inflammation. Br J Ophthalmol (2010) 1.61
A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther (2006) 1.60
The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther (2008) 1.60
Human T-cell memory consists mainly of unexpanded clones. Immunol Lett (2010) 1.60
Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. J Allergy Clin Immunol (2007) 1.60
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis (2012) 1.60